LIVIVO - Search results -

Search results

Result 1 - 10 of total 70

Search options

Article ; Online: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.

Phan, Giao Q / Rosenberg, Steven A

Cancer control : journal of the Moffitt Cancer Center

2013 Volume 20, Issue 4, Page(s) 289–297

Abstract: Background: Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of ... ...

Abstract	Background: Current FDA-approved therapeutic options for patients with metastatic melanoma include dacarbazine, interleukin 2, ipilimumab, vemurafenib, dabrafenib, and trametinib, but long-term tumor regression using available agents remains out of reach for most patients. Adoptive cell transfer (ACT) with autologous tumor-infiltrating lymphocytes (TILs) has shown encouraging results in clinical trials, with evidence of durable ongoing complete responses in patients with advanced melanoma. Emerging techniques to engineer T-cell receptors (TCRs) or chimeric antigen receptors (CARs) using lymphocytes from peripheral blood may offer new tactics in ACT. Methods: We reviewed the literature to provide a synopsis on the development and clinical trial results of ACT, as well as the future outlook for using ACT in patients with metastatic melanoma. Results: ACT with TILs as part of a lymphodepleting regimen has been shown in clinical trials to cause objective clinical responses in approximately 40% to 72% of patients with metastatic melanoma, with up to 40% of those patients experiencing complete responses lasting up to 7 years ongoing. Pilot trials using TCR-engineered cells against melanoma-associated antigens MART-1 and gp100 and the cancer-testis antigen NY-ESO-1 have shown clinical responses in patients with melanoma. CAR cells directed against melanoma have been tested only in preclinical models; however, CAR cells targeting other histologies such as lymphoma have elicited antitumor responses in patients. Conclusions: An example of state-of-the-art personalized medicine, ACT is a potentially curative therapy for patients with metastatic melanoma. Ongoing trials aiming to simplify the regimens may allow a broader range of patients to be treated and enable ACT to be offered by academic cancer centers.
MeSH term(s)	Humans ; Immunotherapy, Adoptive/methods ; Melanoma/immunology ; Melanoma/pathology ; Melanoma/therapy ; Randomized Controlled Trials as Topic ; Skin Neoplasms/immunology ; Skin Neoplasms/pathology ; Skin Neoplasms/therapy
Language	English
Publishing date	2013-09-27
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1328503-8
ISSN	1526-2359 ; 1073-2748
ISSN (online)	1526-2359
ISSN	1073-2748
DOI	10.1177/107327481302000406
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4467: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

Patel, Sapna P / Othus, Megan / Chen, Yuanbin / Wright, G Paul / Yost, Kathleen J / Hyngstrom, John R / Hu-Lieskovan, Siwen / Lao, Christopher D / Fecher, Leslie A / Truong, Thach-Giao / Eisenstein, Jennifer L / Chandra, Sunandana / Sosman, Jeffrey A / Kendra, Kari L / Wu, Richard C / Devoe, Craig E / Deutsch, Gary B / Hegde, Aparna / Khalil, Maya /

Mangla, Ankit / Reese, Amy M / Ross, Merrick I / Poklepovic, Andrew S / Phan, Giao Q / Onitilo, Adedayo A / Yasar, Demet G / Powers, Benjamin C / Doolittle, Gary C / In, Gino K / Kokot, Niels / Gibney, Geoffrey T / Atkins, Michael B / Shaheen, Montaser / Warneke, James A / Ikeguchi, Alexandra / Najera, Jose E / Chmielowski, Bartosz / Crompton, Joseph G / Floyd, Justin D / Hsueh, Eddy / Margolin, Kim A / Chow, Warren A / Grossmann, Kenneth F / Dietrich, Eliana / Prieto, Victor G / Lowe, Michael C / Buchbinder, Elizabeth I / Kirkwood, John M / Korde, Larissa / Moon, James / Sharon, Elad / Sondak, Vernon K / Ribas, Antoni

The New England journal of medicine

2023 Volume 388, Issue 9, Page(s) 813–823

Abstract: Background: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable ... ...

Abstract	Background: Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after surgery (adjuvant therapy), as compared with pembrolizumab given as adjuvant therapy alone, would increase event-free survival among patients with resectable stage III or IV melanoma is unknown. Methods: In a phase 2 trial, we randomly assigned patients with clinically detectable, measurable stage IIIB to IVC melanoma that was amenable to surgical resection to three doses of neoadjuvant pembrolizumab, surgery, and 15 doses of adjuvant pembrolizumab (neoadjuvant-adjuvant group) or to surgery followed by pembrolizumab (200 mg intravenously every 3 weeks for a total of 18 doses) for approximately 1 year or until disease recurred or unacceptable toxic effects developed (adjuvant-only group). The primary end point was event-free survival in the intention-to-treat population. Events were defined as disease progression or toxic effects that precluded surgery; the inability to resect all gross disease; disease progression, surgical complications, or toxic effects of treatment that precluded the initiation of adjuvant therapy within 84 days after surgery; recurrence of melanoma after surgery; or death from any cause. Safety was also evaluated. Results: At a median follow-up of 14.7 months, the neoadjuvant-adjuvant group (154 patients) had significantly longer event-free survival than the adjuvant-only group (159 patients) (P = 0.004 by the log-rank test). In a landmark analysis, event-free survival at 2 years was 72% (95% confidence interval [CI], 64 to 80) in the neoadjuvant-adjuvant group and 49% (95% CI, 41 to 59) in the adjuvant-only group. The percentage of patients with treatment-related adverse events of grades 3 or higher during therapy was 12% in the neoadjuvant-adjuvant group and 14% in the adjuvant-only group. Conclusions: Among patients with resectable stage III or IV melanoma, event-free survival was significantly longer among those who received pembrolizumab both before and after surgery than among those who received adjuvant pembrolizumab alone. No new toxic effects were identified. (Funded by the National Cancer Institute and Merck Sharp and Dohme; S1801 ClinicalTrials.gov number, NCT03698019.).
MeSH term(s)	Humans ; Adjuvants, Immunologic ; Disease Progression ; Melanoma/drug therapy ; Melanoma/pathology ; Melanoma/surgery ; Neoadjuvant Therapy ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology ; Skin Neoplasms/surgery ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use ; Chemotherapy, Adjuvant
Chemical Substances	Adjuvants, Immunologic ; pembrolizumab (DPT0O3T46P) ; Antineoplastic Agents, Immunological
Language	English
Publishing date	2023-02-08
Publishing country	United States
Document type	Clinical Trial, Phase II ; Comparative Study ; Journal Article ; Randomized Controlled Trial
ZDB-ID	207154-x
ISSN	1533-4406 ; 0028-4793
ISSN (online)	1533-4406
ISSN	0028-4793
DOI	10.1056/NEJMoa2211437
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.34: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Synthesis of indolizines through aldehyde–amine–alkyne couplings using metal-organic framework Cu-MOF-74 as an efficient heterogeneous catalyst

Dang, Giao H / Anh T. Nguyen / Dung T. Le / Huy Q. Lam / Nam T.S. Phan / Thanh Truong

Journal of catalysis. 2016 May, v. 337

2016

Abstract: A crystalline copper-based metal-organic framework Cu-MOF-74 was synthesized, and was characterized by X-ray powder diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), thermogravimetric analysis (TGA), Fourier ... ...

Abstract	A crystalline copper-based metal-organic framework Cu-MOF-74 was synthesized, and was characterized by X-ray powder diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), thermogravimetric analysis (TGA), Fourier transform infrared (FT-IR), atomic absorption spectrophotometry (AAS), and nitrogen physisorption measurements. The Cu-MOF-74 exhibited high catalytic activity in the synthesis of indolizines through aldehyde–amine–alkyne three-component coupling transformation and higher than those of other Cu-MOFs such as Cu2(BDC)2(DABCO), Cu3(BTC)2, Cu(BDC), Cu2(NDC)2(DABCO), and Cu4I4(DABCO)2. The reactions could only proceed to produce indolizines in the presence of the solid Cu-MOF catalyst, and contribution from active copper species leached from the solid Cu-MOF-74, if any, was negligible. The Cu-MOF catalyst be recovered and reused several times for the synthesis of indolizines without a significant degradation in catalytic activity. To the best of our knowledge, the synthesis of indolizines using a recyclable heterogeneous catalyst was not previously mentioned in the literature.
Keywords	atomic absorption spectrometry ; catalysts ; catalytic activity ; coordination polymers ; copper ; Fourier transform infrared spectroscopy ; indolizines ; nitrogen ; scanning electron microscopy ; thermogravimetry ; transmission electron microscopy ; X-ray diffraction
Language	English
Dates of publication	2016-05
Size	p. 167-176.
Publishing place	Elsevier Inc.
Document type	Article
ZDB-ID	1468993-5
ISSN	0021-9517
ISSN	0021-9517
DOI	10.1016/j.jcat.2016.02.013
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article ; Online: Modified breast cancer model for preclinical immunotherapy studies.

Katsuta, Eriko / DeMasi, Stephanie C / Terracina, Krista P / Spiegel, Sarah / Phan, Giao Q / Bear, Harry D / Takabe, Kazuaki

The Journal of surgical research

2016 Volume 204, Issue 2, Page(s) 467–474

Abstract: Background: Interest in immunotherapy for breast cancer is rapidly emerging, and applicable animal models that mimic human cancer are urgently needed for preclinical studies. This study aimed to improve a technique for orthotopic inoculation of ... ...

Abstract	Background: Interest in immunotherapy for breast cancer is rapidly emerging, and applicable animal models that mimic human cancer are urgently needed for preclinical studies. This study aimed to improve a technique for orthotopic inoculation of syngeneic breast cancer cells to be used as a preclinical animal model for immunotherapy. Materials and methods: We used our previously reported murine model of orthotopic cancer cell inoculation under direct vision and compared the efficiency of tumorigenesis with tumor cells suspended in either phosphate-buffered saline or Matrigel containing varying numbers of cells. As a model for immune rejection, murine BALB/c-derived 4T1-luc2 breast cancer cells were inoculated orthotopically into both BALB/c and C57BL/6 mice. Results: Matrigel-suspended cells formed larger tumors with higher efficiency than phosphate-buffered saline-suspended cells. The maximum volume of Matrigel that could be inoculated without spillage was 20 μL and 30 μL in the #2 and #4 mammary fat pads, respectively. Tumor take rates increased as the injected cell number increased. In this immune rejection model, there were no significant differences in tumor weight between the strains up to day 7, after which tumor weight decreased in C57BL/6 mice. Bioluminescence in C57BL/6 mice was also significantly less than that in BALB/c mice and increased up to day 7, then swiftly decreased thereafter. Conclusions: This improved technique of innoculating murine breast cancer cells using bioluminescence technology may be useful in evaluating the efficacy of tumor regression mediated by immune responses, as shown by an allogeneic response in C57BL/6 mice.
MeSH term(s)	Adenocarcinoma ; Animals ; Cell Line, Tumor ; Collagen ; Drug Combinations ; Immunotherapy ; Laminin ; Mammary Neoplasms, Experimental ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Proteoglycans
Chemical Substances	Drug Combinations ; Laminin ; Proteoglycans ; matrigel (119978-18-6) ; Collagen (9007-34-5)
Language	English
Publishing date	2016
Publishing country	United States
Document type	Journal Article ; Research Support, U.S. Gov't, Non-P.H.S. ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	80170-7
ISSN	1095-8673 ; 0022-4804
ISSN (online)	1095-8673
ISSN	0022-4804
DOI	10.1016/j.jss.2016.06.003
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 178: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.

Chesney, Jason / Lewis, Karl D / Kluger, Harriet / Hamid, Omid / Whitman, Eric / Thomas, Sajeve / Wermke, Martin / Cusnir, Mike / Domingo-Musibay, Evidio / Phan, Giao Q / Kirkwood, John M / Hassel, Jessica C / Orloff, Marlana / Larkin, James / Weber, Jeffrey / Furness, Andrew J S / Khushalani, Nikhil I / Medina, Theresa / Egger, Michael E /

Graf Finckenstein, Friedrich / Jagasia, Madan / Hari, Parameswaran / Sulur, Giri / Shi, Wen / Wu, Xiao / Sarnaik, Amod

Journal for immunotherapy of cancer

2022 Volume 10, Issue 12

Abstract: Background: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed ...

Abstract	Background: Patients with advanced melanoma have limited treatment options after progression on immune checkpoint inhibitors (ICI). Lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, demonstrated an investigator-assessed objective response rate (ORR) of 36% in 66 patients who progressed after ICI and targeted therapy. Herein, we report independent review committee (IRC)-assessed outcomes of 153 patients treated with lifileucel in a large multicenter Phase 2 cell therapy trial in melanoma. Methods: Eligible patients had advanced melanoma that progressed after ICI and targeted therapy, where appropriate. Melanoma lesions were resected (resected tumor diameter ≥1.5 cm) and shipped to a central good manufacturing practice facility for 22-day lifileucel manufacturing. Patients received a non-myeloablative lymphodepletion regimen, a single lifileucel infusion, and up to six doses of high-dose interleukin-2. The primary endpoint was IRC-assessed ORR (Response Evaluation Criteria in Solid Tumors V.1.1). Results: The Full Analysis Set consisted of 153 patients treated with lifileucel, including longer-term follow-up on the 66 patients previously reported. Patients had received a median of 3.0 lines of prior therapy (81.7% received both anti-programmed cell death protein 1 and anti-cytotoxic lymphocyte-associated protein 4) and had high disease burden at baseline (median target lesion sum of diameters (SOD): 97.8 mm; lactate dehydrogenase (LDH) >upper limit of normal: 54.2%). ORR was 31.4% (95% CI: 24.1% to 39.4%), with 8 complete responses and 40 partial responses. Median duration of response was not reached at a median study follow-up of 27.6 months, with 41.7% of the responses maintained for ≥18 months. Median overall survival and progression-free survival were 13.9 and 4.1 months, respectively. Multivariable analyses adjusted for Eastern Cooperative Oncology Group performance status demonstrated that elevated LDH and target lesion SOD >median were independently correlated with ORR (p=0.008); patients with normal LDH and SOD <median had greater likelihood of response than those with either (OR=2.08) or both (OR=4.42) risk factors. The most common grade 3/4 treatment-emergent adverse events (≥30%) were thrombocytopenia (76.9%), anemia (50.0%), and febrile neutropenia (41.7%).<br />Conclusions: Investigational lifileucel demonstrated clinically meaningful activity in heavily pretreated patients with advanced melanoma and high tumor burden. Durable responses and a favorable safety profile support the potential benefit of one-time lifileucel TIL cell therapy in patients with limited treatment options in ICI-refractory disease.
MeSH term(s)	Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy, Adoptive ; Lymphocytes, Tumor-Infiltrating ; Melanoma/drug therapy ; Skin Neoplasms/drug therapy ; Skin Neoplasms/pathology
Chemical Substances	Immune Checkpoint Inhibitors
Language	English
Publishing date	2022-12-05
Publishing country	England
Document type	Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2022-005755
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.

Phan, Giao Q / Weber, Jeffrey S / Sondak, Vernon K

Annals of surgical oncology

2008 Volume 15, Issue 11, Page(s) 3014–3021

Abstract: Background: CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is a modulatory receptor on T cells involved in downregulating T cell activation. In animal models, CTLA-4 blockade abrogates tolerance to "self" antigens, resulting in the augmentation of ...

Abstract	Background: CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is a modulatory receptor on T cells involved in downregulating T cell activation. In animal models, CTLA-4 blockade abrogates tolerance to "self" antigens, resulting in the augmentation of antitumor immunity and induction of autoimmunity. CTLA-4 blockade by means of monoclonal antibodies (ipilimumab and tremelimumab) has been evaluated in multiple clinical trials in patients with metastatic cancer, mainly those with melanoma and renal cell cancer. Methods: We examine available literature and ongoing clinical trials with ipilimumab and tremelimumab and review our own experience with patients treated with CTLA-4 blockade, with an emphasis on issues of direct relevance to surgical oncologists. Results: CTLA-4 blockade can cause durable tumor regression in patients with metastatic melanoma and other solid tumors. Grade III/IV autoimmune toxicity has been frequently encountered in clinical trials and includes enterocolitis, dermatitis, hypophysitis, uveitis, and hepatitis. Enterocolitis is the most common immune-related adverse event and may cause severe diarrhea requiring intravenous hydration, high-dose corticosteroids, and blockade of tumor necrosis factor alpha with infliximab. Most patients respond to medical treatment, but up to 12% with grade III/IV enterocolitis develop perforation or bleeding that requires colectomy. Conclusions: As more patients are enrolled onto clinical trials involving ipilimumab and tremelimumab, an increasing number of surgeons may be involved in the care of these patients who develop treatment-related complications. In this report, we review the rationale for CTLA-4 blockade and review selected clinical studies published so far with ipilimumab and tremelimumab. We offer guidelines on the management of patients who develop enterocolitis.
MeSH term(s)	Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Antigens, CD/immunology ; CTLA-4 Antigen ; Clinical Trials as Topic ; Enterocolitis/chemically induced ; Enterocolitis/drug therapy ; Guidelines as Topic ; Humans ; Immunotherapy ; Ipilimumab ; Melanoma/drug therapy ; Melanoma/pathology ; Neoplasm Metastasis
Chemical Substances	Antibodies, Monoclonal ; Antigens, CD ; CTLA-4 Antigen ; CTLA4 protein, human ; Ipilimumab ; tremelimumab (QEN1X95CIX)
Language	English
Publishing date	2008-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-008-0104-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients.

Park, Tristen S / Phan, Giao Q / Yang, James C / Kammula, Udai / Hughes, Marybeth S / Trebska-McGowan, Kasia / Morton, Kathleen E / White, Donald E / Rosenberg, Steven A / Sherry, Richard M

Annals of surgical oncology

2017 Volume 24, Issue 4, Page(s) 947–951

Abstract: Background: The use of routine CT imaging for surveillance in asymptomatic patients with cutaneous melanoma is controversial. We report our experience using a surveillance strategy that included CT imaging for a cohort of patients with high-risk ... ...

Abstract	Background: The use of routine CT imaging for surveillance in asymptomatic patients with cutaneous melanoma is controversial. We report our experience using a surveillance strategy that included CT imaging for a cohort of patients with high-risk melanoma. Methods: A total of 466 patients with high-risk cutaneous melanoma enrolled in adjuvant immunotherapy trials were followed for tumor progression by physical examination, labs, and CT imaging as defined by protocol. Evaluations were obtained at least every 6 months for year 1, every 6 months for year 2, and then annually for the remainder of the 5-year study. Time to tumor progression, sites of recurrence, and the method of relapse detection were identified. Results: The patient cohort consisted of 115 stage II patients, 328 stage III patients, and 23 patients with resected stage IV melanoma. The medium time to progression for the 225 patients who developed tumor progression was 7 months. Tumor progression was detected by patients, physician examination or routine labs, or by CT imaging alone in 27, 14, and 59% of cases respectively. Melanoma recurrences were noted to be locoregional in 36% of cases and systemic in 64% of cases. Thirty percent of patients with locoregional relapse and 75% of patients with systemic relapse were detected solely by CT imaging. Conclusions: CT imaging alone detected the majority of sites of disease progression in our patients with high-risk cutaneous melanoma. This disease was not heralded by symptoms, physical examination, or blood work. Although the benefit of the early detection of advanced melanoma is unknown, this experience is relevant because of the rapid development and availability of potentially curative immunotherapies.
MeSH term(s)	Adolescent ; Adult ; Aged ; Asymptomatic Diseases ; Blood Chemical Analysis ; Clinical Trials as Topic ; Disease Progression ; Female ; Humans ; Male ; Melanoma/diagnosis ; Melanoma/secondary ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Staging ; Physical Examination ; Population Surveillance/methods ; Self-Examination ; Skin Neoplasms/diagnosis ; Skin Neoplasms/pathology ; Tomography, X-Ray Computed ; Young Adult
Language	English
Publishing date	2017-01-31
Publishing country	United States
Document type	Journal Article
ZDB-ID	1200469-8
ISSN	1534-4681 ; 1068-9265
ISSN (online)	1534-4681
ISSN	1068-9265
DOI	10.1245/s10434-017-5768-8
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4042: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Sentinel lymph node biopsy for melanoma: indications and rationale.

Phan, Giao Q / Messina, Jane L / Sondak, Vernon K / Zager, Jonathan S

Cancer control : journal of the Moffitt Cancer Center

2009 Volume 16, Issue 3, Page(s) 234–239

Abstract: Background: The disease status of regional lymph nodes is the most important prognostic indicator for patients with melanoma. Sentinel lymph node biopsy (SLNB) was developed as a technique to surgically assess the regional lymph nodes and spare node- ... ...

Abstract	Background: The disease status of regional lymph nodes is the most important prognostic indicator for patients with melanoma. Sentinel lymph node biopsy (SLNB) was developed as a technique to surgically assess the regional lymph nodes and spare node-negative patients unnecessary and potentially morbid complete lymphadenectomies. Methods: We reviewed the literature on SLNB for cutaneous melanoma to provide insight into the rationale for the current widespread use of SLNB. Results: Multiple studies show that the status of the SLN is an important prognostic indicator. Those with positive SLNs have significantly decreased disease-free and melanoma-specific survival compared with those who have negative SLNs. In the Multicenter Selective Lymphadenectomy Trial I (MSLT-I), in which patients with intermediate-thickness melanoma were randomized to SLNB (and immediate completion lymphadenectomy if the SLN was positive) vs observation (and a lymphadenectomy only after presenting with clinically evident recurrence), the 5-year survival rate was 72.3% for patients with positive sentinel nodes and 90.2% for those with negative sentinel nodes (P < .001). Although overall survival was not increased in patients who underwent SLNB compared with those who were randomized to observation, patients who underwent SLNB had a significantly increased 5-year disease-free survival rate compared with those who underwent observation alone (78.3% in the biopsy group and 73.1% in the observation group; P = .009). For those with nodal metastases, patients who underwent SLNB and immediate lymphadenectomy had an increased overall 5-year survival rate compared with those who had lymphadenectomy only after presenting with clinically evident disease (72.3% vs 52.4%; P = .004). Moreover, other studies show that for patients with thin melanomas <or= 1.0 mm, the overall survival rate is significantly worse for those with positive SLNs compared to those with negative SLNs. For thin melanomas, Breslow depth >or= 0.76 mm and increased mitotic rate have been shown to be associated with an increased incidence of SLN metastases. Conclusions: SLNB provides important prognostic and staging data with minimal morbidity and can be used to identify regional node-negative patients who would not benefit from a complete nodal dissection. In our opinion, SLNB should be performed on most patients (with acceptable surgical and anesthesia risk) who have melanomas with a Breslow depth >or= 0.76 mm.
MeSH term(s)	Disease-Free Survival ; Humans ; Melanoma/pathology ; Melanoma/surgery ; Prognosis ; Sentinel Lymph Node Biopsy/methods ; Sentinel Lymph Node Biopsy/trends ; Skin Neoplasms/pathology ; Skin Neoplasms/surgery ; Survival Rate
Language	English
Publishing date	2009-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1328503-8
ISSN	1526-2359 ; 1073-2748
ISSN (online)	1526-2359
ISSN	1073-2748
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4467: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Complete genome sequence of a tenth human polyomavirus.

Buck, Christopher B / Phan, Giao Q / Raiji, Manish T / Murphy, Philip M / McDermott, David H / McBride, Alison A

Journal of virology

2012 Volume 86, Issue 19, Page(s) 10887

Abstract: Nine polyomavirus (PyV) species are known to productively infect humans. The circular DNA genomes of PyVs are readily detectable using rolling circle amplification (RCA). RCA-based analysis of condyloma specimens from a patient with warts, ... ...

Abstract	Nine polyomavirus (PyV) species are known to productively infect humans. The circular DNA genomes of PyVs are readily detectable using rolling circle amplification (RCA). RCA-based analysis of condyloma specimens from a patient with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome demonstrated the presence of a tenth apparently human-tropic polyomavirus species, which we name HPyV10.
MeSH term(s)	DNA Replication ; DNA Restriction Enzymes/metabolism ; Genome, Viral ; Humans ; Immunologic Deficiency Syndromes/virology ; Molecular Sequence Data ; Polyomavirus/genetics ; Polyomavirus/metabolism ; Primary Immunodeficiency Diseases ; Sequence Analysis, DNA ; Skin/virology ; Virus Replication ; Warts/virology
Chemical Substances	DNA Restriction Enzymes (EC 3.1.21.-)
Language	English
Publishing date	2012-09-10
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Intramural
ZDB-ID	80174-4
ISSN	1098-5514 ; 0022-538X
ISSN (online)	1098-5514
ISSN	0022-538X
DOI	10.1128/JVI.01690-12
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 609: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A divergent variant of the eleventh human polyomavirus species, saint louis polyomavirus.

Pastrana, Diana V / Fitzgerald, Peter C / Phan, Giao Q / Raiji, Manish T / Murphy, Philip M / McDermott, David H / Velez, Daniel / Bliskovsky, Valery / McBride, Alison A / Buck, Christopher B

Genome announcements

2013 Volume 1, Issue 5

Abstract: Saint Louis polyomavirus (STLPyV) was recently discovered in human feces. Using random-primed rolling circle amplification combined with deep sequencing, we have found a divergent variant of STLPyV in a sanitized human skin wart specimen. The result ... ...

Abstract	Saint Louis polyomavirus (STLPyV) was recently discovered in human feces. Using random-primed rolling circle amplification combined with deep sequencing, we have found a divergent variant of STLPyV in a sanitized human skin wart specimen. The result strongly suggests that STLPyV directly infects humans and is not simply a dietary contaminant.
Language	English
Publishing date	2013-10-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	2704277-7
ISSN	2169-8287
ISSN	2169-8287
DOI	10.1128/genomeA.00812-13
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito